People | June 10, 2026
Cipla elevates Manoj Dimri as Group Business Head
Pharma industry veteran brings extensive experience in commercial strategy, business growth, and market leadership to his expanded role at Cipla
Pharma industry veteran brings extensive experience in commercial strategy, business growth, and market leadership to his expanded role at Cipla
Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region
The facility sets a new benchmark in respiratory diagnostics
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
_256_384.jpg)
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
